HR Execs on the Move

IconOVir

www.iconovir.com

 
IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer. Our proprietary oncolytic virus platform is based on technology developed by scientific founder Clodagh O`Shea, Ph.D., of the Salk Institute. It is designed to address key limitations of first- and second-generation oncolytic viruses.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.iconovir.com
  • 4570 Executive Drive Suite 350
    San Diego, CA USA 92121
  • Phone: n/a

Executives

Name Title Contact Details
Heather Nagy
HR Director Profile
Mark McCamish
President and Chief Executive Officer Profile

Similar Companies

Certus International Inc

Certus International Inc is a Bedford, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DNA Direct

DNA Direct is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Schleicher and Schuell BioScience

Schleicher & Schuell BioScience is a Keene, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Revolution Medicines

The mission of REVOLUTION Medicines is redesigning evolution`s products to treat serious diseases. The company discovers and develops new drugs by reconfiguring natural substances that are inherently rich with biological function as a result of natural selection. The company`s first drug candidates are innovative small molecules that exploit and improve upon the properties of amphotericin B, a powerful, broad-spectrum antifungal compound found in nature that has avoided generating significant drug resistance in 50 years of clinical use. Headquartered in Redwood City, Calif. at the intersection of Silicon Valley and the birthplace of biotechnology, REVOLUTION Medicines is a private company financed by top-tier investor Third Rock Ventures.

Ligand

Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue. Visit our technical products: omniab.com, captisol.com, vernalis.com and ltptechnology.com.